Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018, Johns Hopkins University
Diabetic blindness caused and reversed “trapped” immune cells in rodent retinas
Retinal blood vessels blocked by immune cells can cause vision loss. Credit: Peter Campochiaro

Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels in the retina, leading to blindness. In experiments that suppressed vascular endothelial growth factor (VEGF) in the eye, researchers were able to re-establish normal blood flow in the retina, offering a potential means of stalling or even reversing diabetes-related blindness.

In the study, published Sept. 21 in the Journal of Clinical Investigation Insight, Johns Hopkins researchers found that increased VEGF levels in the retina attract white blood into the retina, where they adhere to the walls of blood vessels, disrupting . Reducing VEGF or blocking it with an antibody caused the white blood cells to dissipate, opening the closed vessels and restoring blood flow to the area.

"This work is particularly important because it helps explain why and continue to worsen across a patient's lifetime if left untreated," says Peter Campochiaro, M.D., director of the Retinal Cell and Molecular Laboratory and professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute.

The inspiration for the study came from observations made in clinical trials for ranibizumab, a drug designed to block VEGF in patients with diabetic retinopathy and retinal vein occlusion. They saw that after VEGF was suppressed, the patients' conditions not only improved, but the treatment also improved blood flow to parts of the retina that were previously blocked.

"We all believed that this disease caused the blood vessels to die off and was therefore irreversible," says Campochiaro. This skepticism spurred his peers to conduct further studies, which confirmed the observation and heightened his motivation to understand exactly how it occurs. 

To investigate, Campochiaro chose six genetically modified mice to overexpress VEGF when given a drug called doxycycline. After three days of VEGF overexpression, Campochiaro's team observed the telltale clumps of white blood cells collecting in the blood vessels of the retina. The researchers then stopped overexpressing VEGF in these mice, and 17 days later, they found that the white blood cell clumps had broken up and blood flow returned to areas of the retina that had been cut off.

The researchers then explored the cellular signals responsible for the vessel-plugging effects of VEGF. They found that when interacted with VEGF, they were triggered to migrate into the blood vessels of the . The high levels of VEGF also activated a transcription factor, called NF-?B, which is responsible for the expression of many different kinds of proteins in the body. Most importantly, it controls a cell adhesion molecule called VCAM-1, which acts as an adhesive between many types of immune and blood vessels.

The group then repeated their previous experiment, but administered an antibody targeted to inhibit VCAM-1 while also increasing VEGF expression. When compared to the retinal vessels of mice not treated with the inhibitor, the VCAM-1 inhibitor-treated mice showed significantly less white blood cell clumps and better flow in the retinal . This means that VEGF drives the early stages of diabetic retinopathy and retinal vein occlusion, as well as the late stages when vision is decreased, says Campochiaro.

"It would be useful to block VEGF throughout all stages and not just late in the disease when patients are symptomatic. However, this is impractical with our current approaches, which require injection of anti-VEGF proteins into the eye every 4-6 weeks," says Campochiaro.

However, he is hopeful that technology already in development will allow for sustained delivery of anti-VEGF drugs and gene therapy to express anti-VEGF proteins in the eye and will make long-term treatment more feasible. He adds that blocking VCAM-1 could add an additional benefit by further slowing vessel closure and progression of disease.

Diabetic retinopathy is the leading cause of blindness in the U.S., affecting approximately five million adults. Careful management of diabetes and frequent injections of an anti-VEGF agent are effective in reducing the progression to blindness in many patients, but each treatment carries the risk of adverse reactions or infection. Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy.

Explore further: Loss of pericytes deteriorates retinal environment

More information: Yuanyuan Liu et al. Reversible retinal vessel closure from VEGF-induced leukocyte plugging, JCI Insight (2017). DOI: 10.1172/jci.insight.95530

Related Stories

Loss of pericytes deteriorates retinal environment

May 16, 2017
Inside the eye, at the interface between blood vessels and the retina, lies a boundary that prevents harmful substances present in the blood from entering the retina. Researchers at the Center for Vascular Research, within ...

Study suggests new way to prevent vision loss in diabetics and premature babies

March 22, 2017
Researchers at Bascom Palmer Eye Institute, part of the University of Miami Miller School of Medicine, have identified a new molecule that induces the formation of abnormal blood vessels in the eyes of diabetic mice. The ...

Study suggests new way of preventing diabetes-associated blindness

May 25, 2015
Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, ...

Researchers identify new target for abnormal blood vessel growth in the eyes

April 11, 2017
A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization, or abnormal blood vessel growth in the retina, a hallmark of advanced diabetic eye disease (proliferative ...

A drug to treat retinal diseases with drops instead of injections

December 13, 2017
The Spanish firm Sylentis has developed a compound to treat diseases of the retina including age-related macular degeneration and diabetic retinopathy. The treatment is administered by ophthalmic drops instead of intraocular ...

Poor anti-VEGF responses linked to genetic variation in immune regulation

December 5, 2016
Anti-VEGF therapies are commonly used to stabilize deteriorating vision in patients with wet age-related macular degeneration (wet AMD). Vascular endothelial growth factor, or VEGF, is a signaling molecule that helps maintain ...

Recommended for you

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

Ophthalmologists increasingly dissatisfied with electronic health records

December 29, 2017
Ophthalmologists' use of electronic health records (EHR) systems for storing and accessing patients' medical histories more than doubled between 2006 and 2016, while their perceptions of financial and clinical productivity ...

Higher omega-3 fatty acid intake tied to lower glaucoma risk

December 26, 2017
(HealthDay)—Increased daily intake of ω-3 fatty acids is associated with lower odds of glaucoma, but higher levels of total polyunsaturated fatty acid (PUFA) intake are associated with higher odds of developing glaucoma, ...

Protein analysis allows for treatment of eye-disease symptoms with existing drugs

December 21, 2017
Demonstrating the potential of precision health, a team led by a researcher at the Stanford University School of Medicine has matched existing drugs to errant proteins expressed by patients with a rare eye disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.